Please use this identifier to cite or link to this item:
The mechanistic study of Lactobacillus mali APS1 on manipulation of gut microbiome in high-fat diet-induced obesity and non-alcoholic fatty liver disease animal model
gut microbiota,Lactobacillus mali APS1,non-alcoholic fatty liver disease,obesity,short chain fatty acids,
|Publication Year :||2018|
To date, obesity is a widespread disease in developing and developed countries. Some syndromes are accompanied with obesity, such as low grade inflammation and non-alcoholic fatty liver disease (NAFLD). Currently, there are no approved clinical treatment for non-alcoholic fatty liver disease and the difficulty of long-term management has produced a high rate of failure for obesity patients. Therefore, improving the efficacy of obesity and NAFLD treatment is a significant goal. A number of studies indicate that gut microbiota dominates and plays an important role in obesity and non-alcoholic fatty liver disease. Using probiotics to manipulate the gut microbiota has been as the potential approach for improving obesity. However, it remains unclear whether the probiotic can ameliorate the non-alcoholic fatty liver through manipulating the gut microbiota, in addition, the study on the effect of combination of probiotics and diet control in the regulation of obesity-related gut microbiota and metabolites is quite rare. In our previous studies, Lactobacillus mali APS1 (APS1), which is isolated from sugary kefir, has been demonstrated to confer several health benefits in vivo, including amelioration of high-fat diet (HFD)-induced obesity in mice. Therefore, this study aimed to investigate the effect of APS1 on high-fat diet-induced NAFLD and the efficacy of a combination of APS1 and dieting on improvement of obesity in vivo. The results showed that APS1 manipulated the gut microbiota, resulting in reducing the abundance of specific NAFLD-associated bacteria, and significantly reduced hepatic lipid accumulation and increased hepatic antioxidant activity by regulating SIRT-1/Nrf-2 signaling pathway in HFD-fed rats. The combination of APS1 and dieting accelerated body weight loss and reduced fat accumulation though manipulating obesity-associated gut microbiota in preexisting obese mice. Additionally, APS1 intervention modulated the lipid metabolism-associated metabolites, appetitive hormones and increased fecal butyric acid concentration. In conclusion, this study highlighted that APS1 strain isolated from sugary kefir regulating the host gut microbiota and inducing the expressions of short-chain fatty acids and intestinal hormones resulted in reduction of body fat accumulation and hepatic steatosis in vivo. This study provided scientific evidences to show that Lactobacillus mali APS1 can be the potential probiotic to improve metabolic disorder syndrome in the application of functional food.
|Appears in Collections:||生物科技研究所|
Files in This Item:
|10.5 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.